Kichloo Asim, Albosta Michael, Kumar Akshay, Aljadah Michael, Mohamed Mohamed, El-Amir Zain, Wani Farah, Jamal Shakeel, Singh Jagmeet, Kichloo Akif
Department of Internal Medicine, Samaritan Medical Center, Watertown, NY 13601, United States.
Department of Internal Medicine, Central Michigan University, Saginaw, MI 48602, United States.
World J Virol. 2021 Jan 25;10(1):1-29. doi: 10.5501/wjv.v10.i1.1.
The severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019, COVID-19) pandemic has placed a tremendous burden on healthcare systems globally. Therapeutics for treatment of the virus are extremely inconsistent due to the lack of time evaluating drug efficacy in clinical trials. Currently, there is a deficiency of published literature that comprehensively discusses all therapeutics being considered for the treatment of COVID-19. A review of the literature was performed for articles related to therapeutics and clinical trials in the context of the current COVID-19 pandemic. We used PubMed, Google Scholar, and Clinicaltrials.gov to search for articles relative to the topic of interest. We used the following keywords: "COVID-19", "therapeutics", "clinical trials", "treatment", "FDA", "ICU", "mortality", and "management". In addition, searches through the references of retrieved articles was also performed. In this paper, we have elaborated on the therapeutic strategies that have been hypothesized or trialed to-date, the mechanism of action of each therapeutic, the clinical trials finished or in-process that support the use of each therapeutic, and the adverse effects associated with each therapeutic. Currently, there is no treatment that has been proven to provide significant benefit in reducing morbidity and mortality. There are many clinical trials for numerous different therapeutic agents currently underway. By looking back and measuring successful strategies from previous pandemics in addition to carrying out ongoing research, we provide ourselves with the greatest opportunity to find treatments that are beneficial.
严重急性呼吸综合征冠状病毒2（2019冠状病毒病，COVID-19）大流行给全球医疗系统带来了巨大负担。由于在临床试验中评估药物疗效的时间不足，治疗该病毒的疗法极不一致。目前，缺乏全面讨论所有正在考虑用于治疗COVID-19的疗法的已发表文献。针对当前COVID-19大流行背景下与疗法和临床试验相关的文章进行了文献综述。我们使用PubMed、谷歌学术和Clinicaltrials.gov搜索与感兴趣主题相关的文章。我们使用了以下关键词：“COVID-19”、“疗法”、“临床试验”、“治疗”、“FDA”、“ICU”、“死亡率”和“管理”。此外，还对检索到的文章的参考文献进行了搜索。在本文中，我们阐述了迄今为止已被假设或试验的治疗策略、每种疗法的作用机制、支持使用每种疗法的已完成或正在进行的临床试验，以及与每种疗法相关的不良反应。目前，尚无已被证明能在降低发病率和死亡率方面提供显著益处的治疗方法。目前有许多针对多种不同治疗药物的临床试验正在进行。通过回顾并衡量以往大流行中的成功策略，以及开展正在进行的研究，我们为自己提供了找到有益治疗方法的最大机会。
